Moody's assigns B3 CFR rating to Cambrex Corporation; outlook stable
Rating Action: Moody's assigns B3 CFR rating to Cambrex Corporation; outlook stable. Global Credit Research- 04 Nov 2019. New York, November 04, 2019-- Moody's Investors Service assigned ratings to Cambrex Corporation, including a B3 Corporate Family Rating and B3-PD Probability of Default Rating.Cambrex is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The company assists companies in developing processes for the manufacture of clinical and commercial quantities. Product testing, analytical methods and other processes are integrated into the manufacturing process. The company manufactures and tests Active Pharmaceutical Ingredients and Finished Dosage Form at laboratory, clinical and commercial level. The company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry and finished dosage form products and services.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.